Effective January 15, the use of animals to test cosmetic
products in Turkey will be restricted.
Globally, there is a continuing trend of introducing policies to
limit animal testing of cosmetics by prohibiting the sale of
products tested on animals. The European Union has prohibited the
sale of any cosmetic or personal care products tested on animals,
as well as their imported equivalents, since March 11, 2013. This
was followed by marketing and import prohibitions on products
containing ingredients tested on animals.
Following this trend, and to further harmonize Turkish cosmetics
regulations with those of the EU, on July 7, 2015 the Turkish Drug
and Medical Device Institution ("TİTCK") amended the
Cosmetics Regulation to bring it into conformity with EU directives
As of January 15, Turkey prohibits:
placing cosmetic products on the
market where the final formula was developed through animal
placing cosmetic products on the
market containing ingredients or a combination of ingredients that
have been developed through animal testing;
testing ingredients or a combination
of ingredients that have been the subject of animal testing;
performing animal testing on finished
In exceptional circumstances, where serious concerns arise
regarding the safety of an existing cosmetic ingredient, TİTCK
may still grant authorization for animal testing if:
an ingredient is in widespread use
and cannot be replaced by another ingredient able to perform a
similar function; and
the specific human health concern is
substantiated and the need to conduct animal testing is justified
and supported by a detailed research protocol.
For years, TİTCK has demonstrated its commitment to
harmonizing the cosmetic and pharmaceuticals market in Turkey with
EU standards. With these changes for cosmetics, TİTCK has
signaled that it intends further harmonization of the sectors
within its jurisdiction.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
To print this article, all you need is to be registered on Mondaq.com.
Click to Login as an existing user or Register so you can print this article.
The Turkish Ministry of Health ("Ministry") and Social Security Institute ("Institute") announced that according to a new cost savings action plan, pharmaceuticals imported under named-patient sales will occur through the Institute, rather that the Turkish Pharmacists Association ("Association") from 2 May 2017.
The Turkish Competition Board ("Board") recently published a short form decision concluding that the Turkish Pharmacists Association had abused its dominant market position when procuring pharmaceuticals from abroad by executing exclusivity agreements with pharmaceutical suppliers.
Turkey has amended principles for health-related R&D tenders. The changes apply to procurement of R&D services by the Ministry of Health, within the scope of Article 3(f) of Public Tender Act number 4734.
After studying bioengineering and completing a PhD in the San Francisco Bay Area and a two-year postdoctoral research fellowship in London, Mark has spent the past four years analysing global health policy.
Some comments from our readers… “The articles are extremely timely and highly applicable” “I often find critical information not available elsewhere” “As in-house counsel, Mondaq’s service is of great value”
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).